Francesca Dal Pero
Overview
Explore the profile of Francesca Dal Pero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lazzaro C, Fattore G, Barberis M, Buttitta F, Cassoni P, Graziano P, et al.
Pathologica
. 2023 Feb;
115(2):83-89.
PMID: 36790110
Objective: To calculate the full cost of diagnostic pathology tests for Non-Small Cell Lung Cancer (NSCLC) across four Italian Pathology Units. Methods: Pathology Units were located in private (2) and...
2.
Vitulo N, Albiero A, Forcato C, Campagna D, Dal Pero F, Bagnaresi P, et al.
PLoS One
. 2011 Oct;
6(10):e26421.
PMID: 22028874
Wheat is one of the world's most important crops and is characterized by a large polyploid genome. One way to reduce genome complexity is to isolate single chromosomes using flow...
3.
Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M, et al.
Hepatology
. 2009 Aug;
50(4):1038-44.
PMID: 19676127
Unlabelled: Fibrosis progression is the main determinant of liver disease outcome in chronic hepatitis C, being influenced by environmental and host factors. Recently, a cirrhosis risk score (CRS) based on...
4.
Dal Pero F, Maira G, Marin O, Bortoletto G, Pinna L, Alberti A, et al.
J Hepatol
. 2007 Oct;
47(6):768-76.
PMID: 17923166
Background/aims: The hepatitis C virus NS5A protein is phosphorylated by several cellular kinases, including casein kinase 2 (CK2). Little is known about CK2 phosphorylation of NS5A from different HCV genotypes...
5.
Dal Pero F, Tang K, Gerotto M, Bortoletto G, Paulon E, Herrmann E, et al.
J Infect Dis
. 2007 Sep;
196(7):998-1005.
PMID: 17763320
Unlabelled: BACKGROUND. Hepatitis C virus (HCV) genotype 1 is the most prevalent genotype in Western countries, and treatment with pegylated interferon (pegIFN) plus ribavirin fails in 50%-60% of patients. Genetic...
6.
Mirandola S, Realdon S, Iqbal J, Gerotto M, Dal Pero F, Bortoletto G, et al.
Gastroenterology
. 2006 May;
130(6):1661-9.
PMID: 16697730
Background & Aims: Hepatic steatosis is frequent in chronic hepatitis C. Several mechanisms might be implicated, including metabolic cofactors and direct viral effects on intracellular lipid pathways. In a transgenic...
7.
Gerotto M, Dal Pero F, Bortoletto G, Ferrari A, Pistis R, Sebastiani G, et al.
J Hepatol
. 2005 Nov;
44(1):83-7.
PMID: 16271794
Background/aims: Around 15-25% of chronic hepatitis C patients treated with Peg-IFN plus ribavirin become HCV-RNA negative by PCR during therapy but relapse after its withdrawal. We investigated whether minimal residual...
8.
Gerotto M, Dal Pero F, Bortoletto G, Realdon S, Ferrari A, Boccato S, et al.
Antivir Ther
. 2004 Nov;
9(5):763-70.
PMID: 15535414
Pegylated interferon (PEG-IFN) alpha combined with ribavirin is the current standard treatment for hepatitis C, but around 50% of patients do not respond for reasons that are not fully understood....
9.
Realdon S, Gerotto M, Dal Pero F, Marin O, Granato A, Basso G, et al.
J Hepatol
. 2003 Dec;
40(1):77-85.
PMID: 14672617
Background/aims: HCV-CORE protein has been implicated in the regulation of apoptosis of infected cells acting as full-length or C-terminus deleted forms and resulting in both proapoptotic and antiapoptotic effects in...